Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.

Tiago TorresLuis PuigRon VenderCharles LyndeStefano PiasericoJose M CarrascosaPaolo GisondiEsteban DaudénCurdin ConradPedro Mendes-BastosPaulo FerreiraLuiz LeiteJustin D LuJ ValerioM BruniF MessinaA NideggerM Llamas-VelascoE Del AlcazarA MuftiKyra WhiteG CaldarolaLaetitia TeixeiraPaolo RomanelliK DesaiSpyridon GkalpakiotisMarco RomanelliJensen YeungMiguel NogueiraAndrea Chiricozzi

Published in: American journal of clinical dermatology (2021)

In this multinational cohort with 8439 patient-years of follow-up, the cumulative probability of drug survival for all drugs was >79% at 18 months. Prescribed biologic, female sex, higher BMI, and previous exposure to biologic agents were predictors of drug discontinuation. Drug survival of guselkumab and risankizumab was higher than that of ustekinumab, and secukinumab was lower.

Keyphrases

rheumatoid arthritis
adverse drug
drug induced
free survival
body mass index
case report
emergency department
systemic lupus erythematosus
weight gain
weight loss
smoking cessation
disease activity